Results 111 to 120 of about 7,599 (172)

Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer. [PDF]

J Ovarian Res
Ye L, Chen Y, Chen Y, Zhao Q, Cheng X, Wang X, Xu X, Guo W, Chen X, Ni J.   +9 more
europepmc   +1 more source

Phase I/II and window-of-opportunity study of pamiparib and metronomic temozolomide for recurrent isocitrate dehydrogenase mutant gliomas. [PDF]

Neuro Oncol
Schiff D, Ye X, Li J, Ellingson BM, Wen PY, Walbert T, Campian J, Nabors LB, Ozer BH, Desai A, Omuro A, Desideri S, Danda N, Grossman S, Bindra RS.   +14 more
europepmc   +1 more source

Fully protected pyrophosphates <i>via</i> phosphorobromidates for the synthesis of biopolymers. [PDF]

Chem Sci
Wijngaarden S, van der Heijden FLAM, Rijpkema KJ, van Puffelen B, Meeuwenoord NJ, Ramcharan D, van der Marel GA, Codée JDC, Overkleeft HS, Filippov DV.   +9 more
europepmc   +1 more source

Identification of mono-ADP-ribose readers using well-defined photoaffinity-based probes. [PDF]

RSC Chem Biol
van der Heijden FLAM, Weijers SA, Kondyli S, Bleijerveld O, Vermeulen M, Filippov DV.   +5 more
europepmc   +1 more source

Specificity and recognition of the ADP-ribosyl-ubiquitin modification in the DNA damage response. [PDF]

PLoS Biol
Chatrin C, Zhu K, Simmons MDR, Maginn L, Schützenhofer K, Lu Y, Đukić N, Wijngaarden S, Kloet MS, Kliza KW, Heden van Noort GJV, Filippov DV, Ahel D, Smith R, Ahel I.   +14 more
europepmc   +1 more source

ADP-Ribosylation of Cytidine: A Novel Nucleic Acid Modification Reversed by NADAR Hydrolases. [PDF]

Toxins (Basel)
Mikolčević P, Hloušek-Kasun A, Schuller M, Lu Y, Pirović E, Ahel I, Mikoč A.   +6 more
europepmc   +1 more source

The Expanding Landscape of ADP-Ribosylation: Protein, DNA, RNA, and Mitochondrial Regulation. [PDF]

Chem Res Toxicol
Sin YC, Zhao L.
europepmc   +1 more source

Anticancer sensitivities and biological characteristics of HCT116 cells resistant to the selective poly(ADP-ribose) glycohydrolase inhibitor. [PDF]

FEBS Open Bio
Tsuda K, Ogino Y, Sato A.
europepmc   +1 more source

Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations.

JAMA Netw Open
Ostrowski M, Jo Y, Hage Chehade C, Ozay ZI, Gebrael G, Sayegh N, Lin E, Srivastava A, Gordhamer A, Ji R, Li H, Mathew Thomas V, Gupta S, Riaz IB, Maughan BL, Roy S, Agarwal N, Swami U.   +17 more
europepmc   +1 more source

Treatment of HRD-positive elderly ovarian cancer patient: a case report. [PDF]

Anticancer Drugs
Jiang Y, Yi Q, Wang Y, Li C, Liu H.
europepmc   +1 more source